Novel Anti-Viral Therapies for Immunocompromised Patients
Aicuris (aicuris.com) scores 77 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 53rd percentile of 9623 Healthcare brands.
Aicuris is a biopharmaceutical company headquartered in Wuppertal, Germany, founded in 2006. The company focuses on developing novel anti-viral therapies aimed at meeting the needs of immunocompromised patients requiring precise treatment for infections. Aicuris combines scientific research with a pipeline of anti-viral drug candidates, positioning itself as a specialized player bridging scientific discovery and clinical application in the anti-viral treatment space for vulnerable patient populations.
| Brand Name | Aicuris |
|---|---|
| Domain | aicuris.com |
| Industry | Healthcare |
| Founded | 2006 |
| Headquarters | Wuppertal |
| Main Competitors | Gilead Sciences (81/100), Merck & Co. (81/100), Roche (81/100), Shionogi (84/100), ViiV Healthcare, Chimerix |
Moz Domain Authority 34/100 vs category average 41 / leader 97 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Delivering Novel Anti-Viral Therapies to patients with weakened immune systems We are driven to meet the needs of the growing population of immunocompromised pe" (Meta description: 24 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 2 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, + Microdata, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, Facebook, Instagram; no detected presence on X (Twitter), YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Aicuris?", Claude could identify the brand as of September 2026. AiCuris is a German biopharmaceutical company based in Wuppertal, spun out of Bayer in 2006, focused on discovering and developing antiviral and anti-infective drugs. It is known for developing letermovir (Prevymis), an anti-cytomegalovirus drug that it licensed to Merck. Best known for developing letermovir (Prevymis), the CMV antiviral drug licensed to Merck.
When asked "Best brands similar to Aicuris?", Claude would recommend Aicuris as of September 2026. It's a notable player in antiviral drug discovery with a real commercial success story via letermovir, so it's worth mentioning among specialized anti-infective biopharma companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Aicuris's main competitors in Healthcare: Gilead Sciences (81/100), Merck & Co. (81/100), Roche (81/100), Shionogi (84/100).
Sources: Brand Analyzer scan
Aicuris has limited AI-search visibility, scoring 34/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 41, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Aicuris official site
Aicuris was founded in 2006. Aicuris operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Aicuris is headquartered in Wuppertal. Aicuris operates in the Healthcare category.
Sources: Wikidata
Aicuris scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Aicuris official site
Aicuris is a biopharmaceutical company based in Wuppertal, Germany, founded in 2006. It specializes in developing novel anti-viral therapies for patients with weakened immune systems, positioning itself as a company dedicated exclusively to precise anti-viral treatment development.
Sources: Aicuris official site
Aicuris can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Aicuris official site
Aicuris develops anti-viral therapies aimed at treating infections in immunocompromised patients. The company works on translating scientific discoveries into targeted anti-viral treatments, building an expanding pipeline of drug candidates designed to address the specific needs of vulnerable, immune-weakened populations.
Sources: Aicuris official site
Aicuris is known for its specialized focus on anti-viral drug development targeted at immunocompromised patients, distinguishing itself from broader biopharmaceutical companies by concentrating exclusively on this underserved patient population and their infection-related treatment needs.
Sources: Aicuris official site
Aicuris's therapies are intended for immunocompromised patients who require precise anti-viral treatment for infections. The company's target audience also includes healthcare providers and the broader medical community involved in treating vulnerable populations with weakened immune systems.
Sources: Aicuris official site
Aicuris scores 34/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Aicuris has a weak AI-visibility profile at 34/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 34/100 and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Aicuris from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Aicuris: American Hospital Association (AHA) (77/100), AGC Biologics (77/100), Aizon (77/100), American Kinesiotherapy Association (AKTA) (77/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.